Why JNJ Is a Long-Term Winner

Johnson & Johnson (NYSE:JNJ) is one of the Best Wide Moat Dividend Stocks to Invest in.

Johnson & Johnson (NYSE:JNJ) is a long-established leader in the healthcare industry, with a strong portfolio of high-performing drugs in areas like immunology and cancer treatment, along with a thriving medical devices business. In 2023, the company separated its slower-growing consumer health segment, which includes well-known products such as Band-Aids and Tylenol, by launching it as an independent publicly listed firm called Kenvue (KVUE).

In times of economic uncertainty, large and reputable healthcare companies like Johnson & Johnson (NYSE:JNJ) are often considered reliable investment options. The company currently offers a dividend yield of 3.4%. While the dividend remains steady and continues to grow, the stock price itself can vary significantly from year to year. The company holds one of the longest dividend growth streaks in the market, spanning 63 years. It offers a quarterly dividend of $1.30 per share.

In March, Johnson & Johnson (NYSE:JNJ) announced plans to increase its investment in US operations, committing more than $55 billion over the next four years to develop new manufacturing and research facilities. This represents a 25% increase compared to its investment over the previous four years.

While we acknowledge the potential of JNJ as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 10 Best Dividend Stocks for a Bear Market and 10 Best Dividend Stocks to Buy for Dependable Dividend Growth.

Disclosure. None.